Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
about
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases.Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.Transplant biomarkers ready for the clinic?Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.Editorial: Danger Signals Triggering Immune Response and Inflammation.Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.Biomarkers in chronic graft-versus-host disease: quo vadis?Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.Biomarkers for post-transplantation outcomes.Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection.Unraveling the Mechanisms of Cutaneous Graft-Versus-Host Disease.
P2860
Q33593742-7FF1271A-8138-4CEF-AD30-4C286D83AFA8Q33809599-659B83F6-4D68-4559-B1BC-1B14314E9296Q37585026-5444CF88-8D62-4260-8B59-7EC6A45790C4Q38381708-832CE54D-0CAA-4DBF-8B63-6894608683F2Q38800455-997C1A08-7F79-49E7-8BEA-E1F4999EA765Q42345013-7F38E1A2-9105-42C9-9BA1-2F049F1DC04DQ47312420-C35A70A2-85DA-4415-831B-7829D33D1417Q47713449-C3E97DDB-F4E5-4F9C-8336-45035F3F2B1AQ49645938-2FA9DCBA-1B29-40A8-92DD-7185B97A9C9EQ49806345-8B3BD8AD-B8CD-47F7-8894-5286E0D16489Q52603913-6E786F98-1833-4AC7-91BD-1A71D8C53652Q54211996-96B5AA6F-13D6-40E7-B34B-6F0D1AD7268BQ55375763-A3CE4B14-2522-4022-A4A4-0534C0982C07
P2860
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@en
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@nl
type
label
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@en
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@nl
prefLabel
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@en
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@nl
P2093
P2860
P921
P1433
P1476
Plasma biomarkers of risk for ...... teristics post-allogeneic HCT.
@en
P2093
Brent R Logan
Corey Cutler
Jeffrey Yu
Joseph H Antin
Mohammad Abu Zaid
Sung Won Choi
P2860
P304
P356
10.1182/BLOOD-2016-08-735324
P407
P577
2016-11-08T00:00:00Z